2024 ELCC｜先睹为快！一文速览大会重磅中国之声！|广州|报告人|with|lung|cancer

分享至

2024年欧洲肺癌大会（ELCC）将于当地时间3月20日-23日召开。ELCC是肺癌领域的学术盛会，会议将展示该领域最具创新性的科学进展，并探讨肺癌未来的治疗方向。我国专家有多项研究将于本届盛会亮相世界学术舞台，让我们先睹为快！

Proffered Paper session

优选论文专场

摘要号：108O

标题：Surgical Outcomes from RATIONALE-315: Randomized, Double-Blind, Phase 3 Study of Perioperative Tislelizumab with Neoadjuvant Chemotherapy in Resectable NSCLC

报告人：岳东升——天津医科大学肿瘤医院

Mini oral session

迷你口头报告专场

摘要号：1MO

标题：A Phase 3b Study of Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation

报告人：陆舜——上海交通大学附属胸科医院

摘要号：137MO

标题：Phase Ⅱ study of Becotarug (JMT101) Combined With Osimertinib in Patients (pts) With Locally Advanced or Metastatic NSCLC Harboring EGFR Exon 20 Insertion (ex20ins) Mutations (BECOME study）

报告人：张力——中山大学肿瘤防治中心

摘要号：194MO

标题：Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): efficacy and safety results

报告人：张衍——四川大学华西医院

摘要号：196MO

标题：Anlotinib plus Etoposide/Carboplatin (EC) versus Placebo plus EC in First-line Therapy for Extensive-stage Small Cell Lung Cancer (ES-SCLC): A Randomized, Double-blind, Parallel controlled, Phase III Trial ( ETER 701)

报告人：程颖——吉林省肿瘤医院

Poster Session

壁报专场

摘要号：13P

标题：Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy

报告人：韩宝惠——上海交通大学附属胸科医院

摘要号：14P

标题：Consolidative stereotactic radiotherapy in metastatic EGFR-mutant non-small cell lung cancer receiving first-line third-generation EGFR tyrosine kinase inhibitors: A prospective, multicenter, phase II trial

报告人：Yue Zhou——上海

摘要号：15P

标题：Furmonertinib Combined with Anlotinib as the First-line Treatment in Patients with EGFR exon 21 Leu858Arg mutation: Results from FOCUS-A study

报告人：韩宝惠——上海交通大学附属胸科医院

摘要号：17P

标题：Efficacy and safety of Furmonertinib as salvage treatment for EGFR mutated NSCLC patients progressed on third-generation EGFR TKIs

报告人：Xue Hou——广州

摘要号：18P

标题：Preventing CNS Metastasis in EGFR-mutant NSCLC patients Without Baseline CNS Metastasis Using Aumolertinib

报告人：Fang Shen Cun——南京

摘要号：19P

标题：Resistance Mechanism to First-Line Osimertinib in EGFR-Mutated (EGFRm) Advanced NSCLC (aNSCLC) in China: Preliminary data from FLOURISH study

报告人：周建娅——浙江大学医学院附属第一医院

摘要号：20P

标题：Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure: An interim analysis of GPS study

报告人：石远凯——中国医学科学院肿瘤医院

摘要号：21P

标题：NGS and FISH for MET amplification detection in post EGFR-TKI resistant non-small cell lung cancer (NSCLC) patients: a prospective, multi-center study in China

报告人：Qian Zheng——成都

摘要号：23P

标题：Clinical Impact and Prognostic Value of EGFR Mutation Co-occurring with ALK, ROS1, RET Fusions, or MET Exon 14 Skipping Mutations in Chinese Patients with Non-Small Cell Lung Cancer

报告人：Lili Shen——重庆

摘要号：29P

标题：Real-World Safety of Osimertinib in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

报告人：韩宝惠——上海交通大学附属胸科医院

摘要号：32P

标题：Efficacy and safety of furmonertinib for leptomeningeal metastases from EGFR-mutant non-small-cell lung cancer: A real-world retrospective study

报告人：Huan Han——郑州

摘要号：33P

标题：Real-world data of furmonertinib for patients with advanced non-small cell lung cancer with EGFR exon 20 insertion mutations

报告人：Maolin Liu——广州

摘要号：44P

标题：Protecting supernatant cfRNA from cytology samples for the detection of fusions in advanced non-small cell lung cancer (NSCLC)patients

报告人：Zheng Wang——北京

摘要号：49P

标题：Perioperative circulating tumor DNA redefines induced oligometastatic non-small-cell lung cancer at the molecular level

报告人：Rui Fu——广州

摘要号：58P

标题：Molecular characteristics and prognostic value of homologous recombination deficiency (HRD) in non-small cell lung cancer patients

报告人：Zheng Wang——北京

摘要号：61P

标题：First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase 3 study

报告人：周彩存——同济大学附属上海市肺科医院

摘要号：62P

标题：First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small-cell lung cancer (sqNSCLC): 4-yr update from the phase 3 CameL-sq trial

报告人：周彩存——同济大学附属上海市肺科医院

摘要号：65P

标题：Durvalumab combined with chemotherapy and radiotherapy in patients with oligometastatic non-small cell lung cancer (SABRcure)

报告人：Qiwen Li——广州

摘要号：68P

标题：Phase 2 results of ivonescimab (ivo) a novel PD-1/VEGF bispecific in combination with chemotherapy for first line treatment of patients (pts) with advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC)

报告人：张力——中山大学肿瘤防治中心

摘要号：69P

标题：Biomarker-Driven TAM RTK Inhibitor Plus Immunotherapy Would Benefit NSCLC in First-Line Setting: Implications from Phase 3 ORIENT-11 trial

报告人：Anlin Li——广州

摘要号：70P

标题：Phase II Clinical Study of Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as a First-Line Treatment for Driver Gene-Negative Advanced Non-Small Cell Lung Cancer

报告人：Shuanghu Yuan——济南

摘要号：74P

标题：Five-year survival outcomes of camrelizumab in different PD‑L1 expression cohorts of pre‑treated advanced or metastatic NSCLC: a phase 2 study

报告人：Jin-Ji Yang——广州

摘要号：75P

标题：PD-L1 expression and TMB guided first-line sintilimab monotherapy for advanced NSCLC in a multi-center, phase 2 umbrella trial (CTONG 1702)

报告人：Si-Yang M. Liu——广州

摘要号：80P

标题：LILRB2+ Defines a Monocyte Subset Which Identifies Responders of PD-1/PD-L1 Immunotherapy With or Without Chemotherapy in NSCLC

报告人：Linfeng Luo——广州

摘要号：81P

标题：Single-cell and bulk RNA sequencing analysis of the pan-cancer immune microenvironment identifies a novel tumor-associated macrophage signature predicting immunotherapy response

报告人：Yan Zhou——上海

摘要号：82P

标题：Longitudinal Proteomics and Single-cell Transcriptomics Reveal HDAC3 as an Immunotherapy Biomarker in Advanced Non-Small Cell Lung Cancer

报告人：Liyuan Dai——北京

摘要号：83P

标题：Integrating proteomic gene signature-based machine learning model predicts PD-1 monotherapy response in non-small-cell lung cancer

报告人：Xiaoshen Zhang——上海

摘要号：87P

标题：An Artificial Neural Network System to Predict the Response to Sintilimab Based on the RNA Data of ORIENT-3 Study

报告人：Tongji Xie——北京

摘要号：98TiP

标题：Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

报告人：ZhanSheng Jiang——天津

摘要号：100TiP

标题：Phase II Study of Aumolertinib Combined with Local Radiation Therapy for EGFR Mutated Stage Ⅳ NSCLC Patients with oligometastasis

报告人：Fen Zhao——济南

摘要号：101TiP

标题：The Efficacy and Safety of Furmonertinib in Advanced NSCLC Patients with EGFR Mutations and CNS Metastases Based on ctDNA Detection in Peripheral Blood and CSF (FAITH)

报告人：Xiaoyan Li——北京

摘要号：102TiP

标题：A Phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: Beamion LUNG-2

报告人：吴一龙——广东省人民医院

摘要号：105TiP

标题：Adebrelimab combined with famitinib in the treatment of PD-L1≥50% advanced non-small cell lung cancer with brain metastases: A prospective, single-arm trial (BRAIN-AF01)

报告人：Weiran Xu——北京

摘要号：109P

标题：A revised International Association for the Study of Lung Cancer grading system in invasive pulmonary adenocarcinoma: The inclusion of invasive mucinous adenocarcinomas

报告人：Hanyue Li——上海

摘要号：110P

标题：The Role of Extensive Lymph Node Dissection in the New Grading System for Lung Adenocarcinoma

报告人：Chia Liu——台北

摘要号：111P

标题：Enhancing Negative Predictive Value of Landmark Undetectable Molecular Residual Disease with Baseline Cell Free DNA Features-based XGBoost Model in Resected Non-Small Cell Lung Cancer

报告人：张嘉涛——广东省人民医院

摘要号：115P

标题：Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I–III non-small cell lung cancer with high-grade patterns

报告人：Xiaohan Chen——宁波

摘要号：116P

标题：A novel lung nodule localization method：predicting the watershed boundary of target blood vessels with AI simulated dyeing model

报告人：Zihao Chen——广州

摘要号：119P

标题：The role and mechanism of estrogen receptor beta based on SRSF2 in gender differences of lung adenocarcinoma immunotherapy with anti-PD-1

报告人：Hexiao Tang——武汉

摘要号：126P

标题：Adjuvant Aumolertinib for Resected EGFR-Mutated Stage IA2-ⅢA Non-Small-Cell Lung Cancer: Updated Results From A multiple-center real-world experience

报告人：Qingyi Zhang——杭州

摘要号：128TiP

标题：A Phase II, two parallel group study of neoadjuvant and adjuvant targeted treatment in NSCLC with BRAF V600 or MET Exon 14 Mutations

报告人：Shen Zhao——广州

摘要号：135P

标题：Simultaneous Noninvasive Imaging of LAG-3 and PD-L1 for Noninvasive Immunotyping in Lung Cancers

报告人：Lishu Zhao——上海

摘要号：136TiP

标题：A cohort study on the diagnosis of benign or malignant lung nodules based on Synapse 3D software AI devascularization technique

报告人：Qiang Guo——南昌

摘要号：139P

标题：Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis

报告人：Yuelin Han——武汉

摘要号：141P

标题：Integrative Radiomic Analysis of Peri-tumoral and Habitat Zones for Predicting Major Pathological Response to Neoadjuvant Immunotherapy and Chemotherapy in Non-Small Cell Lung Cancer: a multicenter, retrospective, cohort study

报告人：Wei Huang——济南

摘要号：143P

标题：Efficacy and Safety of Aumolertinib(AUM) With Radiotherapy Versus Concurrent Chemoradiotherapy(cCRT) in the Treatment of Unresectable Stage III EGFR-mutant NSCLC: A Multicenter, Randomized, Open-Label Phase III Study (ADVANCE)

报告人：Nan Bi——深圳

摘要号：144P

标题：Preliminary safety and efficacy of iruplinalkib after chemoradiotherapy (CRT) in ALK/ROS1+ unresectable non‑small cell lung cancer (NSCLC): Part 1 results from the INNOVATION study

报告人：Linlin Wang——济南

摘要号：148P

标题：Neoadjuvant EGFR-TKI combined with Chemotherapy improves the Complete Response Rate in Operable EGFR-mutant NSCLC Patients : A Multicenter real-world Study

报告人：Wanpu Yan——北京

摘要号：159P

标题：Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB–IIIB lung squamous cell carcinoma

报告人：Jia C. Liu——杭州

摘要号：160P

标题：Perioperative and Patient Reported Outcomes of Robotic-Assisted and Video-Assisted Thoracoscopic Surgery for Patients with NSCLC Receiving Neoadjuvant Immunotherapy: A Real-World Cohort Study

报告人：Shaowei Wu——广州

摘要号：169P

标题：Genomic landscape of NSCLC brain metastases and its potential association with TP53 and tumor mutation burden: a territory-wide program in Hong Kong

报告人：Tsz Yeung Kam——香港

摘要号：172P

标题：Real World Data of Anolotinib for Lung Cancers with Liver Metastases in China

报告人：Minglei Zhuo——北京

摘要号：173P

标题：Surgery versus Stereotactic Body Radiation Therapy as Initial Treatment for Pulmonary Oligometastases from Colorectal Cancer: A Propensity Score Analysis

报告人：Yaqi Wang——北京

摘要号：174P

标题：Intracranial (IC) Activity of Ivonescimab (ivo) Alone or In Combination with Platinum Doublet Chemotherapy (PC) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC) and Brain Metastases (BMs)

报告人：张力——中山大学肿瘤防治中心

摘要号：198P

标题：Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small-cell lung cancer (LS-SCLC): safety run-in results of a phase 3 trial

报告人：程颖——吉林省肿瘤医院

摘要号：200P

标题：Comparison of Irinotecan/carboplatin versus Etoposide/carboplatin for extended disease small cell lung cancer (ED-SCLC): A systematic review and meta-analysis of randomized controlled trials.

报告人：Zeeshan Afzal——太原

摘要号：205P

标题：Efficacy and Safety of Neoadjuvant Chemotherapy with or without PD-L1/PD-1 Inhibitors in Surgically Limited-Stage Small-Cell Lung Cancer

报告人：Liang Shi——北京

摘要号：213P

标题：Comprehensive Genomic Atlas of Small Cell Lung Cancer Finds PKD1L1 Mutation Associated with Poor Prognosis and Drug Susceptibility

报告人：Haiyong Wang——济南

摘要号：216TiP

标题：A phase II study of consolidation Serplulimab following hypofractionated radiotherapy with concurrent chemotherapy for patients with limited stage small cell lung cancer（ASTRUM-LC01）

报告人：Yuqi Wu——北京

摘要号：217P

标题：Redox-high lung adenocarcinoma driven by KEAP1/STK11/SMARCA4 mutation shapes immune-desert tumor microenvironment and attenuates the efficacy of immunotherapy

报告人：Xuuewu Wei——广州

摘要号：218P

标题：DSG2+ cancer stem cells co-located with POSTN+ myofibroblasts in the tumor boundary that determines the efficacy of immunotherapy in non-small cell lung cancer

报告人：Guangyu Fan——北京

摘要号：221P

标题：Single-cell transcriptomics reveals CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer

报告人：Yaokai Wen——广州

摘要号：222P

标题：Mutational variant allele frequency profile as a biomarker of response to immune checkpoint inhibitors in non-small cell lung cancer

报告人：Ruyun Gao——北京

摘要号：224P

标题：LCerebrospinal Fluid-Based Mutation Abundance Index (MAI) Correlated to Clinical Outcome in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer with EGFR Mutations

报告人：Wenjie Zhu——北京

摘要号：225P

标题：Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.

报告人：Wenhua Liang——广州

摘要号：231P

标题：Cancer-associated fibroblast expressed Nicotinamide N-methyltransferase is negatively associated with metastasis of lung adenocarcinomas.

报告人：Peiyu Wang——北京

摘要号：232P

标题：Tumor Spread Through Air Spaces Is an Independent Predictor of Recurrence-free Survival in Patients with Resected Pulmonary Lymphoepithelial Carcinoma

报告人：Pei-Hsing Chen——台湾

摘要号：233P

标题：Predictive Value of Immunohistochemistry Assessment of Mutated p53 for Response and Survival Outcomes in Patients with Lung Squamous Cell Cancer Following Neoadjuvant Immunochemotherapy

报告人：Xuhua Huang——深圳

摘要号：237P

标题：Genomic Profiling of Aggressive Pathologic Features in Lung Adenocarcinoma

报告人：Yi-Duo Lin——广州

摘要号：239P

标题：The new IASLC grading system for invasive lung adenocarcinoma predicts the prognosis of patients receiving neoadjuvant immunotherapy

报告人：Haijie Xu——汕头

摘要号：240P

标题：Feasibility of Detecting NSCLC-Associated Fusion Genes in Long-Term Preserved FFPE Samples

报告人：林冬梅——北京大学肿瘤医院

摘要号：243P

标题：FOXP4 promotes lung cancer cell proliferation and invasion by regulating tumor-associated macrophage polarization through the β-catenin/FOSL2/ARID5A signaling pathway

报告人：QIN YAN——成都

备注：排名不分先后，按照摘要号进行排序如有遗漏或任何问题，请给我们留言~

撰写：Babel

排版：Babel

执行：Uni

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。

Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.